GlobalData analysed the number of clinical trials examining cystic fibrosis with start dates...
Coronavirus treatment: Vaccines/drugs in the pipeline for COVID-19
Here are the potential human coronavirus vaccines/drugs pharmaceutical companies across the world are developing following the Wuhan coronavirus outbreak (COVID-19).
United Therapeutics’ Tyvaso meets goals in PH-ILD patients
United Therapeutics has reported that the Tyvaso (treprostinil) inhalation solution met all primary and secondary endpoints in the Phase III INCREASE trial involving patients with pulmonary hypertension caused by interstitial lung disease (PH-ILD).
Novartis discontinues asthma drug candidate fevipiprant following another Phase III trial failure
Shares in Gossamer Bio, which has a lead drug candidate with a similar mechanism of action to fevipiprant, fell following Novartis’ recent announcement.
Novartis asthma drug fevipiprant fails in Phase III trials
Novartis has said that fevipiprant (QAW039) failed to meet goals in Phase III LUSTER-1 and LUSTER-2 clinical trials involving patients suffering from inadequately controlled moderate-to-severe asthma (GINA Steps 4 and 5).
resTORbio halts clinical development of RTB101 in respiratory illness
resTORbio has announced plans to stop the clinical development of RTB101 in the prevention of clinically symptomatic respiratory illness (CSRI) after its Phase III PROTECTOR 1 clinical trial failed to meet the primary goal.
TRIKAFTA (elexacaftor, ivacaftor and tezacaftor) for the Treatment of Cystic Fibrosis
TRIKAFTA is the first triple combination therapy containing elexacaftor, ivacaftor, and tezacaftor indicated for the treatment of cystic fibrosis (CF) in people aged 12 years and above and having a F508del mutation and one minimal function mutation.
Seqster and La Jolla Institute of Immunology partner on asthma study
Seqster has signed a three-year licensing deal and partnership with La Jolla Institute of Immunology (LJI) to support the execution of a $6.9m Asthma study.
Boehringer begins enrolment in Phase II BALANCE-CF1 trial
Boehringer Ingelheim has enrolled the first patient in the Phase II BALANCE-CF study investigating an inhaled epithelial sodium channel (ENaC) inhibitor, BI 1265162, to treat cystic fibrosis.